This is a continuation of a long topic, addressed by post number rather than by page. Start at post 1 · go to the accepted answer.
Oral versus injected administration claims for BPC-157: the preclinical work studied injection. Oral claims are common in supplier marketing and poorly supported by published evidence. If you are comparing orality between compounds, that is a distinction worth noting.
Not the whole picture, but the part of it I can speak to.
Post #31 is the version of this I will quote in future. One addition.
Stability of BPC-157 in solution: what has been measured in published work covers specific formulations under specific conditions. Extrapolating to a reconstituted preparation in a different diluent at a different concentration is an extrapolation, acknowledged as one.
That matches what I was told, which is not the same as knowing it.
I had written a reply contradicting post #31 and deleted it. Here is what survived.
Stability in solution is the practical constraint. Dry, these keep well; reconstituted, the supplier's own data usually covers a shorter period than people assume.
I am reporting what happened, not recommending it.
Confirming post #35 from a second method, which matters more than confirming it from a second person.
Anecdote is the whole of the human evidence base here, and this community's convention is to say so rather than to aggregate anecdotes into something that sounds like data.
Written in the hope of being told what I have missed.
Offering a way to settle absence of controlled human data rather than another opinion about it. Two measurements, taken the same way, a fortnight apart. If the difference is within the noise, the question was not answerable at this precision.
Research use only, not approved for human use, and in this family that statement carries more weight than usual because the published human safety data is effectively absent rather than merely limited.
Coming back to post #35, because the follow-up matters more than the original answer.
Mechanistic accounts in this area run well ahead of the outcome data. Angiogenesis and cell migration effects in a dish are real observations and are a long way from a clinical result.
I am aware this is the third time this month I have made this point.
BPC-157: the preclinical literature is extensive, mostly from a small number of research groups, and reports effects across a wide range of injury models. The breadth of reported effects is itself worth noting — a compound that improves outcomes in tendon, muscle, gut, nerve and bone through a single mechanism would be remarkable, and remarkable claims deserve proportionate scrutiny.
Post #41 is right about the mechanism and I think understates the practical bit.
Analytical identity of BPC-157: a 15-residue peptide with an unambiguous mass (≈1419.5 Da). Identity confirmation by LC-MS is trivially easy, which means there is no excuse for an unverified identity on this compound.
One of those cases where knowing the mechanism does not help the decision.
This settles it for me, at least until somebody posts a reason it should not.
Post #42 and I disagree about the size of the effect, not about the direction.
Absence of controlled human data came up in a thread eighteen months ago and was answered well. I cannot find it, which is itself the problem, so here is the reconstruction.
What would change the position on repair peptides: adequately powered, published, peer-reviewed randomised controlled human trials with pre-specified outcomes. That is the standard applied to every other therapeutic claim on this site and it is the standard applied here.
I have written this out at length because the short version keeps being misread.
For anyone arriving from search engines: this subcategory discusses published preclinical work and the absence of published clinical work. It does not endorse or recommend these compounds.
I will take the caveat as seriously as the claim, which is the point of putting it there.
I would call the community position on absence of controlled human data likely rather than established, and I would be comfortable defending that hedge.
BPC-157's published evidence is overwhelmingly preclinical and mostly rodent. That is not a dismissal — it is the state of the literature, and any discussion that starts elsewhere is starting from something that is not there.
Before the thread moves on from absence of controlled human data — what is the sample size behind the claim? I am not being difficult; I have seen the same figure quoted from an n of four and from an n of four hundred.
I read post #50 twice before replying, because I had assumed the opposite.
Where I have landed on absence of controlled human data, having got it wrong once in public: the direction is clear, the magnitude is not, and anyone quoting a precise magnitude has borrowed it from somewhere that did not measure it.
The pentadecapeptide sequence is short and stable enough to survive conditions that would degrade a larger peptide, which is one of the few things about it that is well characterised.
The right answer here may simply be that it has not been measured.
Absence of controlled human data is one of those subjects where the general answer and the answer for a specific case diverge, and the thread will go in circles until someone says which one is being asked for.
Coming back to post #53, because the follow-up matters more than the original answer.
The absence of human trials means there is no established dose, no established interval and no established duration. Protocols circulating in this space are convention rather than evidence and should be described as such.
For anyone arriving from search engines: this subcategory discusses published preclinical work and the absence of published clinical work. It does not endorse or recommend these compounds.
Post #57 put the caveat in the right place and I want to underline it.
The distinction between "no evidence it works" and "evidence it does not work": we have the first for these compounds. That is genuinely different from the second and the distinction matters, but it also means treatment plans based on these compounds are being built on theoretical grounds, not empirical ones.
This is where my knowledge stops and I would rather mark the edge than blur it.
Building on post #57 rather than restating it.
BPC-157's published evidence is overwhelmingly preclinical and mostly rodent. That is not a dismissal — it is the state of the literature, and any discussion that starts elsewhere is starting from something that is not there.
Anyone with a larger sample, please post it.